Skip to main content
SpringerLink
Log in

Cost burden of hepatitis C therapies high for payers

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 US dollars

Reference

  • van Boemmel-Wegmann S, et al. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Digestive Diseases and Sciences : 14 Jan 2020. Available from: URL: http://doi.org/10.1007/s10620-019-06037-z

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost burden of hepatitis C therapies high for payers. PharmacoEcon Outcomes News 846, 8 (2020). https://doi.org/10.1007/s40274-020-6547-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6547-5

Search

Navigation